Resumen
El empleo de los inhibidores de la glucoproteína IIb/IIIa en el contexto del síndrome coronario agudo sin elevación del segmento ST es un tema muy controvertido. A pesar de la oposición a su uso en las últimas guías de revascularización de la Sociedad Europea de Cardiología, los autores seguimos defendiendo el beneficio de la estrategia utilizada en el ensayo clínico TACTICS: actitud intervencionista facilitada con tirofibán en los pacientes con riesgo moderado y alto. Argumentamos esta defensa basándonos en que consideramos que el tirofibán es superior a los otros inhibidores de la glucoproteína IIb/IIIa en estos pacientes, unido a las dudas que todavía nos plantea la bivalirudina y al convencimiento de que los nuevos antiagregantes no deben considerarse sustitutivos, sino complementarios.
Palabras clave
Síndromes coronarios agudos
Antiagregación plaquetaria
Protocolos clínicos
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction): Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons.
Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.
Circulation, (2007), 116 pp. 803-877
[2.]
F.M. Task, B. Jean-Pierre, W.H. Christian, A. Diego, B. Eric, B. Andrzej, et al.
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology.
Eur Heart J, (2007), 28 pp. 1598-1660
[3.]
F. Worner, P. Álvarez-García, A. Ariza.
Concepto, clínica, diagnóstico y esquema terapéutico general del síndrome coronario agudo sin elevación del segmento ST.
Manual del síndrome coronario agudo, 1.a ed, Sociedad Española de Cardiología, pp. 77-92
[4.]
E.M. Antman, M. Cohen, P.J.L.M. Bernink, C.H. McCabe, T. Horacek, G. Papuchis, et al.
The TIMI Risk Score for Unstable Angina/Non-ST Elevation MI: A Method for Prognostication and Therapeutic Decision Making.
JAMA, (2000), 284 pp. 835-842
[5.]
K.A.A. Fox, O.H. Dabbous, R.J. Goldberg, K.S. Pieper, K.A. Eagle, F. Van de Werf, et al.
Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE).
BMJ, (2006), 333 pp. 1091
[6.]
C.P. Cannon, W.S. Weintraub, L.A. Demopoulos, R. Vicari, M.J. Frey, N. Lakkis, et al.
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
N Engl J Med, (2001), 344 pp. 1879-1887
[7.]
W. Wijns, P. Kolh, N. Danchin, M.C. Di, V. Falk, T. Folliguet, et al.
Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).
Eur Heart J, (2010), 31 pp. 2501-2555
[8.]
A.W. Bonz, B. Lengenfelder, J. Strotmann, S. Held, O. Turschner, K. Harre, et al.
effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
J Am Coll Cardiol, (2002), 40 pp. 662-668
[9.]
P.A. Gurbel, K.P. Bliden, K.A. Zaman, J.A. Yoho, K.M. Hayes, U.S. Tantry.
Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study.
Circulation, (2005), 111 pp. 1153-1159
[10.]
A. Kastrati, J. Mehilli, F.J. Neumann, F. Dotzer, J. Ten Berg, H. Bollwein, et al.
Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial.
JAMA, (2006), 295 pp. 1531-1538
[11.]
D.R. Phillips, I.F. Charo, L.V. Parise, L.A. Fitzgerald.
The platelet membrane glycoprotein IIb-IIIa complex.
Blood, (1988), 71 pp. 831-843
[12.]
S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, et al.
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
N Engl J Med, (2007), 357 pp. 2001-2015
[13.]
L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, C. Held, et al.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
N Engl J Med, (2009), 361 pp. 1045-1057
[14.]
M. O’Donoghue, E.M. Antman, E. Braunwald, S.A. Murphy, P.G. Steg, A. Finkelstein, et al.
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
J Am Coll Cardiol, (2009), 54 pp. 678-685
[15.]
G.W. Stone, B.T. McLaurin, D.A. Cox, M.E. Bertrand, A.M. Lincoff, J.W. Moses, et al.
Bivalirudin for patients with acute coronary syndromes.
N Engl J Med, (2006), 355 pp. 2203-2216
[16.]
C.P. Cannon, A. Battler, R.G. Brindis, J.L. Cox, S.G. Ellis, N.R. Every, et al.
American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee) Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, American College of Emergency Physicians, American Heart Association, Cardiac Society of Australia & New Zealand, National Heart Foundation of Australia, Society for Cardiac Angiography and Interventions, and the Taiwan Society of Cardiology.
J Am Coll Cardiol, (2001), 38 pp. 2114-2130
[17.]
A.K. Rao, C. Pratt, A. Berke, A. Jaffe, I. Ockene, T.L. Schreiber, et al.
Thrombolysis in myocardial infarction (TIMI) trial--Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
J Am Coll Cardiol, (1988), 11 pp. 1-11
[18.]
J.F. Díaz, J.M. De La Torre, M. Sabaté, J. Goicolea.
Registro Español de Hemodinámica y Cardiología Intervencionista. XIX Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990–2009).
Rev Esp Cardiol, (2010), 63 pp. 1304-1316
[19.]
The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators.
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
N Engl J Med, (2006), 354 pp. 1464-1476
[20.]
K.P. Alexander, A.Y. Chen, M.T. Roe, L.K. Newby, C.M. Gibson, N.M. Allen-LaPointe, et al.
The CRUSADE investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
JAMA, (2005), 294 pp. 3108-3116
[21.]
M. De Carlo, G. Borelli, R. Gistri, N. Ciabatti, A. Mazzoni, M. Arena, et al.
Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes.
Cathet Cardiovasc Intervent, (2009), 74 pp. 408-415
[22.]
S.S. Jolly, S. Amlani, M. Hamon, S. Yusuf, S.R. Mehta.
Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials.
Am Heart J, (2009), 157 pp. 132-140
[23.]
G.W. Stone, M.E. Bertrand, J.W. Moses, E.M. Ohman, A.M. Lincoff, J.H. Ware, et al.
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: The ACUITY Timing Trial.
JAMA., (2007), 297 pp. 591-602
[24.]
R.P. Giugliano, J.A. White, C. Bode, P.W. Armstrong, G. Montalescot, B.S. Lewis, et al.
Early versus delayed, provisional eptifibatide in acute coronary syndromes.
N Engl J Med, (2009), 360 pp. 2176-2190
[25.]
Royal Collage of Physicians. The National Clinical Guideline Centre. Unstable Angina and NSTEMI: the early management of unstable angina and non-ST-segmentelevation myocardial infarction [publicadas 24 Mar 2010]. Disponible en: http://guidance.nice.org.uk/CG94/NICEGuidance/pdf/English.
[26.]
L. Bolognese, G. Falsini, F. Liistro, P. Angioli, K. Ducci, T. Taddei, et al.
Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: The EVEREST Trial.
J Am Coll Cardiol, (2006), 47 pp. 522-528
[27.]
A.W.J. Van’t Hof, S.T. De Vries, J.H. Dambrink, K. Miedema, H. Suryapranata, J.C.A. Hoorntje, et al.
A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study.
Eur Heart J, (2003), 24 pp. 1401-1405
[28.]
M. Roffi, D.P. Chew, D. Mukherjee, D.L. Bhatt, J.A. White, D.J. Moliterno, et al.
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.
Eur Heart J, (2002), 23 pp. 1441-1448
[29.]
The Platelet Receptor inhibition In Ischemic Syndrome Management (PRISM-PLUS) study investigators.
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
N Engl J Med, (1998), 338 pp. 1488-1497
[30.]
The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators.
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
N Engl J Med, (1998), 338 pp. 1498-1505
[31.]
The PARAGON Investigators.
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina.
Circulation, (1998), 97 pp. 2386-2395
[32.]
The Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON)-B Investigators.
Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes.
Circulation, (2002), 105 pp. 316-321
[33.]
The PURSUIT Trial Investigators.
Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
N Engl J Med, (1998), 339 pp. 436-443
[34.]
Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
Lancet, (2001), 357 pp. 1915-1924
[35.]
M. Roffi, D.P. Chew, D. Mukherjee, D.L. Bhatt, J.A. White, C. Heeschen, et al.
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-STsegment-elevation acute coronary syndromes.
Circulation, (2001), 104 pp. 2767-2771
[36.]
S.R. Mehta, C.P. Cannon, K.A.A. Fox, L. Wallentin, W.E. Boden, R. Spacek, et al.
Routine vs selective invasive strategies in patients with acute coronary syndromes: A collaborative meta-analysis of randomized trials.
JAMA, (2005), 293 pp. 2908-2917
[37.]
R.J. De Winter, F. Windhausen, J.H. Cornel, P.H.J.M. Dunselman, C.L. Janus, P.E.F. Bendermacher, et al.
Early invasive versus selectively invasive management for acute coronary syndromes.
N Engl J Med, (2005), 353 pp. 1095-1104
[38.]
K.M. Akkerhuis, J.H. Alexander, B.E. Tardiff, E. Boersma, R.A. Harrington, A.M. Lincoff, et al.
Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?.
Circulation, (2002), 105 pp. 554-556
[39.]
D.A. Morrow, M.S. Sabatine, E.M. Antman, C.P. Cannon, E. Braunwald, P. Theroux.
Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).
J Am Coll Cardiol, (2004), 94 pp. 774-776
[40.]
E. Boersma, R.A. Harrington, D.J. Moliterno, H. White, P. Thqroux, F. Van de Werf, et al.
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
Lancet, (2002), 359 pp. 189-198
[41.]
G.B. Danzi, C. Capuano, M. Sesana, L. Mauri, F.B. Sozzi.
Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.
Am J Cardiol, (2006), 97 pp. 489-493
[42.]
D.J.M. Schneider, P.Q.M. Baumann, D.A.M. Whitaker, B.E.M. Sobel.
Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
J Cardiovasc Pharmacol, (2005), 46 pp. 41-45
[43.]
D.J. Schneider, F.K. Keating, P.Q. Baumann, D.A. Whitaker, B.E. Sobel.
Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus.
Coron Artery Dis, (2006), 17 pp. 57-61
[44.]
E.D. Peterson, C.V. Pollack Jr., M.T. Roe, L.S. Parsons, K.A. Littrell, J.G. Canto, et al.
Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: Observations from the National Registry of Myocardial Infarction 4.
J Am Coll Cardiol, (2003), 42 pp. 45-53
[45.]
S.V. Manoukian, F. Feit, R. Mehran, M.D. Voeltz, R. Ebrahimi, M. Hamon, et al.
Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes. An analysis from the ACUITY trial.
J Am Coll Cardiol, (2007), 49 pp. 1362-1368
Copyright ©
2011. Sociedad Española de Cardiología